Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial Lipid-Lowering Drugs Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me